At the forefront of research into prevention of scar tissue formation after a heart attack

HEMEX is a proud partner of the European Consortium, that was awarded €4.5 million by the European Union for the ELR-SCAR project to validate a novel hydrogel biomaterial for prevention of scar tissue forming in the heart following a heart attack. This project will transform and fundamentally improve clinical practice in this crucial field of cardiology, resulting in a reduction of the enormous burden that MI and its leading cause, IHD, places on society as a whole and on the individual patient.

More info @University of Galway



HEMEX is a global provider of clinical research services to small and medium-sized life sciences companies in diverse therapeutic areas. By combining extensive clinical expertise, commitment to speed, and dedication to patient-centric approaches, HEMEX supports its clients to complete their clinical trials faster. Advancing healthcare and improving patient outcomes, HEMEX’s priority is ensuring patients can have access to lifesaving therapies within a short clinical journey. Through its subsidiaries, Hemex Germany GmbH and Hemex Benelux AV, the company can also secure project funding through different EU funds. For more information, visit